Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 29c
Tweet
Share
E-mailGet Alerts SYRS Hot Sheet
Join SI Premium – FREE
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($1.43), $0.29 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $3.94 million.
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- Qualcomm expects $40bn in non-handset revenue by fiscal 2029
- Qualcomm targets $40B in non-handset revenue by fiscal 2029
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
